Donald D StevensonSummaryAffiliation: Scripps Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Selection of patients for aspirin desensitization treatmentDonald D Stevenson
Division of Allergy, Asthma and Immunology, Scripps Clinic and the Scripps Research Institute, La Jolla, CA 92037, USA
J Allergy Clin Immunol 118:801-4. 2006- Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory diseaseDonald D Stevenson
Division of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla, CA 92037, USA
J Allergy Clin Immunol 116:755-60. 2005.... - The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory diseaseAndrew A White
Scripps Clinic, La Jolla, California 92037, USA
Ann Allergy Asthma Immunol 95:330-5. 2005..The blocking effect of controller medications for asthma could have an effect on the outcome of aspirin challenges in patients suspected of having aspirin-exacerbated respiratory disease (AERD)... - Clinical and pathologic perspectives on aspirin sensitivity and asthmaDonald D Stevenson
Division of Allergy, Asthma and Immunology and the Department of Medicine, Scripps Clinic and the Scripps Research Institute, La Jolla, USA
J Allergy Clin Immunol 118:773-86; quiz 787-8. 2006.... - Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trialSven Erik Dahlen
Experimental Asthma and Allergy Research, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Am J Respir Crit Care Med 165:9-14. 2002..Addition of a leukotriene receptor antagonist such as montelukast improves asthma in aspirin-intolerant patients over and above what can be achieved by glucocorticosteroids... - Failure to maintain an aspirin-desensitized state in a patient with aspirin-exacerbated respiratory diseaseAndrew A White
Naval Medical Center San Diego, Allergy and Immunology Clinic, San Diego, California 92106, USA
Ann Allergy Asthma Immunol 97:446-8. 2006..Aspirin desensitization is a useful therapy in patients with aspirin-exacerbated respiratory disease... - Effect of leukotriene modifier drugs on the safety of oral aspirin challengesAndrew White
Department of Allergy and Immunology, Naval Medical Center San Diego, San Diego, California 92106, USA
Ann Allergy Asthma Immunol 97:688-93. 2006..Aspirin-exacerbated respiratory disease can be diagnosed with oral aspirin challenges and treated with aspirin desensitization... - Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory diseaseJennifer Y Lee
Division of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla, CA 92037, USA
J Allergy Clin Immunol 119:157-64. 2007..Prior studies used 650 mg of aspirin twice daily, but studies at lower dosages were inconclusive... - The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challengesAdam N Williams
Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, CA 92130, USA
J Allergy Clin Immunol 120:273-7. 2007.... - Aspirin sensitivity: implications for patients with coronary artery diseaseRaghava R Gollapudi
Divison of Cardiovascular Diseases, Scripps Clinic and the Scripps Research Institute, La Jolla, Calif 92037, USA
JAMA 292:3017-23. 2004..Large-scale trials are warranted to determine the safety and efficacy of acetylsalicylic acid desensitization therapy in patients with concomitant CAD because data are currently limited to small case series... - Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory diseaseKatharine M Woessner
Scripps Clinic Medical Group, The Scripps Research Institute, La Jolla, California 92037, USA
Ann Allergy Asthma Immunol 93:339-44. 2004..Despite accumulating data on the safety of COX-2 selective inhibitors in AERD, concern still remains that high doses of a COX-2 inhibitor may be sufficient to induce a cross-reaction... - Nonsteroidal anti-inflammatory drug-induced reactions and desensitizationM Pilar Berges-Gimeno
Allergy Service, Hospital Sur, Madrid, Spain
J Asthma 41:375-84. 2004 - The safety of celecoxib in patients with aspirin-sensitive asthmaKatharine M Woessner
Scripps Clinic and the Scripps Research Institute, La Jolla, California 92037, USA
Arthritis Rheum 46:2201-6. 2002..To determine whether celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, cross-reacts in patients with aspirin-exacerbated respiratory disease (AERD) with asthma... - The natural history and clinical characteristics of aspirin-exacerbated respiratory diseaseM Pilar Berges-Gimeno
Scripps Clinic, La Jolla, California 92037, USA
Ann Allergy Asthma Immunol 89:474-8. 2002..The disease progressed over the 13 years between historical onset and current evaluation, with more sinusitis and need for controller medications over time. There was no ethnic or familial distribution of AERD... - Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory diseaseM Pilar Berges-Gimeno
Scripps Research Institute and Scripps Clinic and Scripps Research Institute, La Jolla, Calif 92037, USA
J Allergy Clin Immunol 111:180-6. 2003..CONCLUSION: Aspirin desensitization followed by daily aspirin is efficacious by at least the first 6 months of treatment and continues to be effective for up to 5 years of follow-up... - Aspirin desensitization in patients with AERDDonald D Stevenson
Division of Allergy, Asthma, and Immunology, Scripps Clinic and the Scripps Research Institute, La Jolla, CA 92037, USA
Clin Rev Allergy Immunol 24:159-68. 2003..Those who respond to systemic steroids or have intractable or recurrent nasal polyps are particularly well-suited for this therapeutic intervention... - Pathogenesis of aspirin-exacerbated respiratory diseaseDonald D Stevenson
Allergy and Immunology Division, Scripps Clinic and the Scripps Research Institute, La Jolla, CA 92037, USA
Clin Rev Allergy Immunol 24:169-88. 2003..It is more likely that a diminution in number or function of cysLT receptors accounts for the diminished inflammatory response found in ASA desensitization... - Aspirin and NSAID sensitivityDonald D Stevenson
Division of Allergy, Asthma, and Immunology, Department of Medicine, Scripps Clinic and the Scripps Research Institute, W 205, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
Immunol Allergy Clin North Am 24:491-505, vii. 2004..COX-2 inhibitors do not cross-react; however, all NSAIDs, including the selective COX-2 inhibitors, can sensitize patients and induce urticaria or anaphylaxis on next exposure to the drug... - Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitisAdile Berna Dursun
Division of Allergy, Asthma and Immunology, Scripps Health Graduate Education Department, Ataturk Chest Diseases and Thoracic Surgery, Training and Research Hospital, Ankara, Turkey
Ann Allergy Asthma Immunol 100:420-5. 2008..A definitive diagnosis of aspirin-exacerbated respiratory disease (AERD) requires a positive oral aspirin challenge (OAC), but predicting which patients will have positive challenges is often difficult... - Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory diseaseM Pilar Berges-Gimeno
The Scripps Research Institute, La Jolla, California 92037, USA
Ann Allergy Asthma Immunol 90:338-41. 2003..7 to 5.9 mg daily (P = 0.0003). CONCLUSIONS: Our study suggests that ASA desensitization treatment is effective during the first 4 weeks of daily treatment with ASA... - Evidence-based protocols for oral NSAID challengesDonald D Stevenson
J Pediatr 148:704-5; author reply 705-6. 2006 - Aspirin-induced asthma: advances in pathogenesis, diagnosis, and managementAndrew Szczeklik
Department of Medicine, Jagellonian University School of Medicine, Krakow, Poland
J Allergy Clin Immunol 111:913-21; quiz 922. 2003..Aspirin desensitization, followed by daily aspirin treatment, is a valuable therapeutic option in most patients with AIA, particularly those with recurrent nasal polyposis or overdependence on systemic corticosteroids... - Cross-reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitorsRonald A Simon
Ann Allergy Asthma Immunol 94:8-11. 2005